59.51

0.52% -0.31

After Hours: 59.51

Exelixis Inc (EXEL)

Overview News Price History Option Chain Financials Discussions Forecast

Exelixis Inc stock is traded at $59.51, with a volume of 2.62M. It is down -0.52% in the last 24 hours and up +6.04% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Previous Close:

$59.82

Open:

$60

24h Volume:

2.62M

Relative Volume:

1.07

Market Cap:

$14.75B

Revenue:

$2.38B

Net Income/Loss:

$833.42M

P/E Ratio:

19.72

EPS:

3.0172

Net Cash Flow:

$917.69M

1W Performance:

+2.02%

1M Performance:

+6.04%

6M Performance:

+32.36%

1Y Performance:

+54.81%

1-Day Range:

$58.59

$60.00

1-Week Range:

$57.88

$61.66

52-Week Range:

$33.76

$61.66

Exelixis Inc Stock (EXEL) Company Profile

Name

Exelixis Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(650) 837-7000

Address

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Employee

1,077

Twitter

@exelixisinc

Next Earnings Date

2026-11-03

Latest SEC Filings

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXEL Exelixis Inc	59.51	14.75B	2.38B	833.42M	917.69M	3.0172
VRTX Vertex Pharmaceuticals Inc	485.22	122.98B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	216.25	86.33B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	753.12	77.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	802.64	50.47B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.44	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-26	Initiated	BMO Capital Markets	Market Perform
Aug-06-26	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-25-26	Resumed	Truist	Hold
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform
Sep-19-25	Resumed	Barclays	Equal Weight
Sep-17-25	Resumed	Barclays	Equal Weight
Sep-17-25	Initiated	Goldman	Buy
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform
Sep-19-24	Initiated	UBS	Neutral
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-23	Initiated	BTIG Research	Buy
Dec-15-23	Initiated	Citigroup	Buy
Sep-26-23	Initiated	H.C. Wainwright	Buy
Aug-22-23	Reiterated	Oppenheimer	Outperform
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight
May-10-23	Resumed	Piper Sandler	Overweight
Mar-09-23	Initiated	Wells Fargo	Overweight
Jan-26-23	Initiated	Credit Suisse	Outperform
Oct-18-22	Initiated	JMP Securities	Mkt Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-03-21	Resumed	Jefferies	Buy
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Reiterated	H.C. Wainwright	Buy
Jun-15-21	Initiated	H.C. Wainwright	Buy
May-18-21	Resumed	Goldman	Sell
Mar-31-21	Initiated	Credit Suisse	Outperform
Mar-12-21	Initiated	Wolfe Research	Outperform
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Nov-13-19	Initiated	BofA/Merrill	Buy
Mar-18-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-17-18	Initiated	Goldman	Neutral
Sep-10-18	Initiated	Morgan Stanley	Underweight
May-11-18	Reiterated	Needham	Buy
Oct-17-17	Reiterated	Needham	Buy
Oct-17-17	Reiterated	RBC Capital Mkts	Outperform
Oct-16-17	Reiterated	SunTrust	Buy
Sep-22-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-12-17	Reiterated	Needham	Buy
Jul-14-17	Initiated	SunTrust	Buy
Mar-31-17	Initiated	Needham	Buy
Mar-16-17	Initiated	Oppenheimer	Perform
Feb-28-17	Downgrade	Stifel	Buy → Hold
Nov-03-16	Initiated	Deutsche Bank	Buy
Oct-10-16	Upgrade	Piper Jaffray	Neutral → Overweight
Sep-15-16	Reiterated	Stifel	Buy

View All

Exelixis Inc Stock (EXEL) Latest News

01:08 AM

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

01:08 AM

Oct 12, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Oct 12, 2026

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Oct 12, 2026

Oct 10, 2026

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Oct 10, 2026

Oct 09, 2026

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

Oct 09, 2026

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Oct 08, 2026

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Oct 08, 2026

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026